Limits...
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C - Cancer Biother. Radiopharm. (2015)

Bottom Line: Treatment with DC-TC was associated with longer OS in both cohorts.Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025).This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

View Article: PubMed Central - PubMed

Affiliation: 1 Caladrius Biosciences, Inc. , Irvine, California.

ABSTRACT
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous tumor cells (DC-TC) showed superior survival compared with similar patients immunized with irradiated tumor cells (TC). We wished to determine whether this difference was evident in cohorts who at the time of treatment had (1) no evidence of disease (NED) or (2) had detectable disease. Eligibility criteria and treatment schedules were the same for all three trials. Pooled data confirmed that overall survival (OS) was longer in 72 patients treated with DC-TC compared with 71 patients treated with TC (median OS 60 versus 22 months; 5-year OS 51% versus 32%, p=0.004). Treatment with DC-TC was associated with longer OS in both cohorts. Among 70 patients who were NED at the time that treatment was started, OS was better for DC-TC: 5-year OS 73% versus 43% (p=0.015). Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025). This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

No MeSH data available.


Related in: MedlinePlus

OS for patients with metastatic melanoma who at the time of treatment had NED (n=70) compared with those who had detectable disease (n=73), p=0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4492594&req=5

f3: OS for patients with metastatic melanoma who at the time of treatment had NED (n=70) compared with those who had detectable disease (n=73), p=0.001.

Mentions: The difference in survival for patients based on whether or not they were NED at the time of treatment is shown in Figure 3. As expected, survival was much better for those who were NED at the time that ASI was initiated with a median survival not reached at 5 years versus 25.5 months, and 5-year survival of 56% versus 27% (p=0.001).


Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C - Cancer Biother. Radiopharm. (2015)

OS for patients with metastatic melanoma who at the time of treatment had NED (n=70) compared with those who had detectable disease (n=73), p=0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4492594&req=5

f3: OS for patients with metastatic melanoma who at the time of treatment had NED (n=70) compared with those who had detectable disease (n=73), p=0.001.
Mentions: The difference in survival for patients based on whether or not they were NED at the time of treatment is shown in Figure 3. As expected, survival was much better for those who were NED at the time that ASI was initiated with a median survival not reached at 5 years versus 25.5 months, and 5-year survival of 56% versus 27% (p=0.001).

Bottom Line: Treatment with DC-TC was associated with longer OS in both cohorts.Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025).This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

View Article: PubMed Central - PubMed

Affiliation: 1 Caladrius Biosciences, Inc. , Irvine, California.

ABSTRACT
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous tumor cells (DC-TC) showed superior survival compared with similar patients immunized with irradiated tumor cells (TC). We wished to determine whether this difference was evident in cohorts who at the time of treatment had (1) no evidence of disease (NED) or (2) had detectable disease. Eligibility criteria and treatment schedules were the same for all three trials. Pooled data confirmed that overall survival (OS) was longer in 72 patients treated with DC-TC compared with 71 patients treated with TC (median OS 60 versus 22 months; 5-year OS 51% versus 32%, p=0.004). Treatment with DC-TC was associated with longer OS in both cohorts. Among 70 patients who were NED at the time that treatment was started, OS was better for DC-TC: 5-year OS 73% versus 43% (p=0.015). Among 73 patients who had detectable metastases, OS was better for DC-TC: median 38.8 months versus 14.7 months, 5-year OS 33% versus 20% (p=0.025). This approach is promising as an adjunct to other therapies in patients who have had metastatic melanoma.

No MeSH data available.


Related in: MedlinePlus